Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-26-035886
Filing Date
2026-03-30
Accepted
2026-03-30 06:08:47
Documents
75
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0283661-6k_kazia.htm   iXBRL 6-K 22266
2 HALF-YEAR REPORT FOR THE SIX MONTHS ENDED DECEMBER 31, 2025 ea028366101ex99-1.htm   iXBRL EX-99.1 755394
3 GRAPHIC ea028366101_ex99-1img1.jpg GRAPHIC 1766
4 GRAPHIC ea028366101_ex99-1img2.jpg GRAPHIC 2519
  Complete submission text file 0001213900-26-035886.txt   3816390

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE kzia-20251231.xsd EX-101.SCH 59233
6 XBRL CALCULATION FILE kzia-20251231_cal.xml EX-101.CAL 32883
7 XBRL DEFINITION FILE kzia-20251231_def.xml EX-101.DEF 152634
8 XBRL LABEL FILE kzia-20251231_lab.xml EX-101.LAB 317531
9 XBRL PRESENTATION FILE kzia-20251231_pre.xml EX-101.PRE 173748
79 EXTRACTED XBRL INSTANCE DOCUMENT ea0283661-6k_kazia_htm.xml XML 611776
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 26809794
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)